RAPT vs. CYRX, CDMO, IGMS, TRDA, SIGA, YMAB, OLMA, TVTX, HRTX, and CMPS
Should you be buying RAPT Therapeutics stock or one of its competitors? The main competitors of RAPT Therapeutics include Cryoport (CYRX), Avid Bioservices (CDMO), IGM Biosciences (IGMS), Entrada Therapeutics (TRDA), SIGA Technologies (SIGA), Y-mAbs Therapeutics (YMAB), Olema Pharmaceuticals (OLMA), Travere Therapeutics (TVTX), Heron Therapeutics (HRTX), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical preparations" industry.
RAPT Therapeutics (NASDAQ:RAPT) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
RAPT Therapeutics has a net margin of 0.00% compared to Cryoport's net margin of -50.17%. Cryoport's return on equity of -15.19% beat RAPT Therapeutics' return on equity.
RAPT Therapeutics currently has a consensus price target of $24.67, suggesting a potential upside of 515.13%. Cryoport has a consensus price target of $18.25, suggesting a potential upside of 77.53%. Given RAPT Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe RAPT Therapeutics is more favorable than Cryoport.
RAPT Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.
In the previous week, Cryoport had 1 more articles in the media than RAPT Therapeutics. MarketBeat recorded 2 mentions for Cryoport and 1 mentions for RAPT Therapeutics. Cryoport's average media sentiment score of 0.74 beat RAPT Therapeutics' score of 0.43 indicating that Cryoport is being referred to more favorably in the news media.
Cryoport has higher revenue and earnings than RAPT Therapeutics. Cryoport is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.
99.1% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Cryoport shares are owned by institutional investors. 6.6% of RAPT Therapeutics shares are owned by insiders. Comparatively, 10.1% of Cryoport shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Cryoport received 150 more outperform votes than RAPT Therapeutics when rated by MarketBeat users. However, 66.17% of users gave RAPT Therapeutics an outperform vote while only 65.21% of users gave Cryoport an outperform vote.
Summary
Cryoport beats RAPT Therapeutics on 10 of the 18 factors compared between the two stocks.
Get RAPT Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RAPT Therapeutics Competitors List
Related Companies and Tools
